Intech Biopharm Corporation
Taipei Exchange 6461.TWO
Intech Biopharm Corporation Revenue for the year ending December 31, 2023: USD 841.94 K
Intech Biopharm Corporation Revenue is USD 841.94 K for the year ending December 31, 2023, a 9.15% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
-
Intech Biopharm Corporation Revenue for the year ending December 31, 2022 was USD 771.39 K, a -45.03% change year over year.
-
Intech Biopharm Corporation Revenue for the year ending December 31, 2021 was USD 1.40 M, a 87.01% change year over year.
-
Intech Biopharm Corporation Revenue for the year ending December 31, 2020 was USD 750.36 K.
Key data
| Date | Revenue | Gross Profit | Operating Income | EBIT |
|---|
Market news
Loading...
Taipei Exchange: 6461.TWO
| CEO | Mr. Wei-Shiu Wu |
| IPO Date | July 15, 2014 |
| Location | |
| Headquarters | No. 36, Ruiguang Road |
| Employees | 82 |
| Sector | Health Care |
| Industries | |
Description
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email